Frontiers in Clinical Drug Research - CNS and Neurological Disorders.

Format:

Book

Author/Creator:

Atta-ur-Rahman.

Contributor:

Amtul, Zareen.

Series:

Frontiers in Clinical Drug Research - CNS and Neurological Disorders

Language:

English

Subjects (All):

Nervous system--Diseases.

Nervous system.

Central nervous system.

Physical Description:

1 online resource (279 pages)

Edition:

1st ed.

Place of Publication:

UAE : Bentham Science Publishers, 2021.

Summary:

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The ninth volume of this series features reviews that cover the following topics related to the treatment of a different CNS disorders, related diseases and basic neuropharmacology research: - Integrating imaging and microdialysis into systems neuropharmacology - Depression heterogeneity and the potential of a transdiagnostic and dimensional approach to identify biologically relevant phenotypes - CAR-T cells in brain tumors and autoimmune diseases - from basics to the clinic - Revaluation of thyrotropin-releasing hormone and its mimetics as candidates for treating a wide range of neurological and psychiatric disorders - Natural BACE1 inhibitors: promising drugs for the management of Alzheimer's disease - The possibilities of safe lithium therapy in the treatment of neurological and psychoemotional disorders - Pharmacotherapy of multiple sclerosis and treatment strategies.

Contents:

Cover

Title

Copyright

End User License Agreement

Contents

Preface

List of Contributors

Integrating Imaging and Microdialysis into Systems Neuropharmacology

Carla Biesdorf1 and Robert E. Stratford1,*

INTRODUCTION

MICRODIALYSIS OVERVIEW

INTEGRATION OF MICRODIALYSIS WITH PET IMAGING

Measurement of Brain Metabolic Activity

Demonstration of Drug Delivery to the Brain

Demonstration of Drug Binding to Target by Displacement of Tracer Binding

Alteration of Tracer Binding in Response to Drug Treatment and in Disease

Assessment of Neurotransmitter Concentrations

INTEGRATION OF MICRODIALYSIS WITH MRI

Microdialysis and Structural MRI

Microdialysis and MRS

Microdialysis and fMRI

INTEGRATION OF MICRODIALYSIS AND EEG MONITORING

Seizures

Sleep Disorders

Miscellaneous Diseases

INTEGRATION OF MICRODIALYSIS WITH OTHER IMAGING MODALITIES

Computed Tomography Imaging

Mass Spectrometry Imaging

SPECT Imaging

INTEGRATED USE OF IMAGING AND MICRODIALYSIS IN ALZHEIMER'S DISEASE RESEARCH

Pathology of AD

Pharmacologic Treatment of AD

Biomarkers of AD

Potential Applications for Integrated Use of Imaging and Microdialysis in AD Research

SUMMARY AND CONCLUSIONS

CONSENT FOR PUBLICATION

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

Depression Heterogeneity and the Potential of a Transdiagnostic and Dimensional Approach to Identify Biologically Relevant Phenotypes

Zoya Marinova1,*

THE HETEROGENEITY OF MAJOR DEPRESSIVE DISORDER

MELANCHOLIC AND ATYPICAL DEPRESSION

Biological Correlates of Melancholic and Atypical Depression

Genetic Markers

Biochemical Markers

Treatment Response

DEPRESSION WITH MANIC OR HYPOMANIC SYMPTOMS

Depression with Manic or Hypomanic Symptoms

DATA-DRIVEN DEPRESSION SUBTYPES.

COMBINING BIOLOGICAL AND CLINICAL FINDINGS BASED ON THE TRANSDIAGNOSTIC DIMENSIONAL APPROACH APPLIED BY THE RESEARCH DOMAIN CRITERIA (RDOC) PROJECT

THERAPEUTIC IMPLICATIONS OF THE HETEROGENEITY OF DEPRESSION

CAR-T Cells in Brain Tumors and Autoimmune Diseases - from Basics to the Clinic

Mansour Poorebrahim1,*, Niloufar Mohammadkhani2,3, Mohammad Foad Abazari4, Elham Fakhr1,5, Isaac Quiros-Fernandez1,5, Solmaz Sadeghi6 and Angel Cid-Arregui1

1. INTRODUCTION

2. DEVELOPMENTS IN CAR-T CELLS

2.1. CAR-T cell generations

2.2. Next-Generation CAR Platforms

3. VEHICLES FOR CAR DELIVERY

3.1. Viral Vectors

3.2. Non-Viral Technologies

4. PRODUCTION AND INFUSION OF CAR-T CELLS TO THE BRAIN

4.1. Isolation and Enrichment of T Cells

4.2. Activation of T Cells

4.3. Transduction of T Cells

4.4. Expansion of CAR-T Cells

4.5. Formulation of CAR-T Cells

4.6. CAR-T Cell Infusion To The Brain

5. CAR-T CELL THERAPY OUTCOME IN BRAIN TUMORS

6. CAR-T CELL THERAPY OUTCOME IN AUTOIMMUNE DISEASES

7. POTENTIAL CHALLENGES AND CONCLUDING REMARKS

Revaluation of Thyrotropin-Releasing Hormone and Its Mimetics as Candidates for Treating a Wide Range of Neurological and Psychiatric Disorders

Naotake Kobayashi1,* and Tsuyoshi Kihara2

What is Thyrotropin-Releasing Hormone?

TRH Receptors

Specific Degradation Enzymes of TRH

Pyroglutamyl Aminopeptidase (PAPs)

Thyroliberinase (Pyroglutamyl Peptidase-II)

Prolyl Endopeptidase (PEP)

Histidylprolinamide Imidopeptidase

PHYSIOLOGICAL ACTIVITIES OF TRH AND TRH MIMETICS

CNS Effects

Neurotransmitters and Neuromodulators

Locomotor Activation

Thermoregulation.

Neuroprotective Effect

Endocrine Effects

Thyroid-Stimulating Hormone (TSH) Release

Prolactin (PRL) Secretion

CHALLENGES FOR THE DISCOVERY OF TRH MIMETICS

N-Terminus Part Modified Type

Taltirelin (TA-0910)

Azetirelin (YM-14673)

Orotirelin (CG-3509)

Montirelin (CG-3703, NS-3)

DN-1417

JTP-2942

Middle Part Modified Type

NP-647

[1-Benzyl-His2]TRH

CNS Permeable Prodrugs (CPPs)

TRH-Like Peptide and its Prodrugs

C-Terminus Part Modified Type

RX77368

N-Terminus and Middle Part Modified Type

Posatirelin (RGH-2202)

N- and C-Terminus Part Modified Type

MK-771

All Parts Modified Type

Rovatirelin (KPS-0373, S-0373)

TRH-Based Compound

JAK4D

THERAPEUTIC APPLICATION OF TRH AND ITS MIMETICS FOR NEUROLOGICAL, PSYCHIATRIC AND OTHER DISORDERS

Spinocerebellar Degeneration (SCD)

Spinal Muscular Atrophy (SMA)

Parkinson's Disease (PD)

Alzheimer's Disease (AD)

Amyotrophic Lateral Sclerosis (ALS)

Epilepsy

Depression

Schizophrenia

Pain

CURRENT STATUS OF TRH MIMETICS IN CLINICAL DEVELOPMENT

VISION OF FUTURE ADVANCES OF TRH AND ITS MIMETICS

CONCLUSION

ABBREVIATIONS

Natural BACE1 Inhibitors: Promising Drugs for the Management of Alzheimer's Disease

Richa Shri1,*, Varinder Singh2, Ravinder Kaur1 and Shiveena Bhatia2

THE IMPLICATION OF BACE1 IN AD PATHOGENESIS

BACE1: A PROMISING THERAPEUTIC TARGET FOR THE MANAGEMENT OF AD

BOTANICALS IN BACE1 INHIBITION

ABRONIA NANA (COMMON NAME: DWARF SAND VERBENA

FAMILY: NYCTAGINACEAE)

ALPINIA OFFICINARUM (COMMON NAME: LESSER GALANGAL

FAMILY: ZINGIBERACEAE)

ANGELICA DAHURICA (COMMON NAME: CHINESE ANGELICA, ROOT OF THE HOLY GHOST

FAMILY: UMBELLIFERAE).

ARALIA CORDATA (COMMON NAME: MOUNTAIN ASPARAGUS

FAMILY: ARALIACEAE)

CAMELLIA SINENSIS (COMMON NAME: TEA

FAMILY: THEACEAE)

CEPHALOTAXUS HARRINGTONIA VAR. FASTIGIATA (COMMON NAME: JAPANESE PLUM-YEW

FAMILY: CEPHALOTAXACEAE)

CORNUS OFFICINALIS (COMMON NAME: JAPANESE CORNEL

FAMILY: CORNACEAE)

COPTIS CHINENSIS (COMMON NAME: CHINESE GOLDTHREAD

FAMILY: RANUNCULACEAE)

CROCUS SATIVUS L. (COMMON NAME: SAFFRON

FAMILY: IRIDACEAE)

CURCUMA LONGA (COMMON NAME: TURMERIC

EISENIA BICYCLIS (COMMON NAME: ARAME, SEA OAK

FAMILY: LESSONIACEAE)

FICUS BENJAMINA VAR. NUDA (COMMON NAME: WEEPING FIG

FAMILY: MORACEAE)

GLYCYRRHIZA GLABRA (COMMON NAME: LIQUORICE

FAMILY: FABACEAE)

LAVANDULA LUISIERI (COMMON NAME: CASTILLIAN LAVENDER

FAMILY: LAMIACEAE)

LYCOPODIELLA CERNUA (COMMON NAME: STAGHORN CLUBMOSS

FAMILY: LYCOPODIACEAE)

MAGNOLIA OFFICINALIS (COMMON NAME: HOUPU MAGNOLIA

FAMILY: MAGNOLIACEAE)

MORUS LHOU (COMMON NAME: BAIGELN MULBERRY

NELUMBO NUCIFERA (COMMON NAME: INDIAN LOTUS

FAMILY: NELUMBONACEAE)

OLEA EUROPAEA (COMMON NAME: OLIVE

FAMILY: OLEACEAE)

PANAX GINSENG (COMMON NAME: CHINESE GINSENG

PERILLA FRUTESCENS (COMMON NAME: BEEFSTEAK PLANT

PODOCARPUS MACROPHYLLUS VAR. MACROPHYLLUS (COMMON NAME: YEW PLUM PINE

FAMILY: PODOCARPACEAE)

PUNICA GRANATUM (COMMON NAME: POMEGRANATE

FAMILY: PUNICACEAE)

SMILAX CHINA (COMMON NAME: CHINESE ROOT

FAMILY: SMILACACEAE)

SOPHORA FLAVESCENS (COMMON NAME: SHRUBBY SOPHORA

FUTURE DIRECTION

The Possibilities of Safe Lithium Therapy in the Treatment of Neurological and Psychoemotional Disorders.

Anna V. Shurlygina1,2, Lyubov N. Rachkovskaya1, Margarita V. Robinson1, Anastasia A. Kotlyarova1, Maxim A. Korolev1,2 and Andrey Yu. Letyagin1

MECHANISM OF ACTION OF LITHIUM MEDICATIONS

APPLICATION OF LITHIUM MEDICATIONS IN ANIMALS MODELING VARIOUS PATHOLOGIES

LITHIUM MEDICATIONS IN CLINICAL PRACTICE

SAFE WAYS TO IMPLEMENT THE EFFECTS OF LITHIUM IN THERAPY

EXPERIMENTAL STUDY OF THE EFFECTS OF THE LITHIUM COMPLEX ON BEHAVIOR AND ELECTRIC ACTIVITY OF THE BRAIN IN HEALTHY MICE AND RATS

Effects of the Lithium Complex on Animals' Adaptation to Physical Stress, Social Adaptation and Aggressive Behavior

Influence of the Lithium Complex on the Development of a Complex Conditional Drinking Reflex During Caffeine and Alcoholic Intoxication

Effects of the Lithium Complex on the Behavior of Mice with a Conditioned Reflex in a Plus-maze Test During Caffeine and Alcohol Intoxication [62]

Effect of Lithium Drugs on Electrophysiological Activity of the Brain

Effects of the Lithium Complex on the Behavior of Mice in a Chronic Social Stress Model

Therapeutic Effects of the Lithium Complex on Mice with a formed Anxiety-Depression State

Protective Effects of the Lithium Complex on the Development of an Anxiety-Depression State in Mice in the Stages of its Formation

Effects of the Lithium Complex on the ЗH-8-OH-DPAT Binding in the Brain of Mice with Anxiety-Depression State

LIST OF ABBREVIATIONS

Pharmacotherapy of Multiple Sclerosis and Treatment Strategies

Amany Ragab1,*, Ali Ibrahim2, Rania Helal3, Ahmed Elsaid4, Hossam Younis5, Mona Elsherbiny6 and Takwa Elkhatib7

TREATMENT OF RELAPSES IN MULTIPLE SCLEROSIS

Intravenous Methylprednisolone.

Adrenocorticotropic Hormone (ACTH)(Acthar® Gel).

Notes:

Description based on publisher supplied metadata and other sources.

Other Format:

Print version: Atta-ur-Rahman Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 9

ISBN:

9781681089041

1681089041

OCLC:

1286431521